Industrial Strategy Life Sciences Sector Deal 2 Industrial Strategy Life Sciences Sector Deal 2 Foreword Last year the Life Sciences develops to encourage and spread Sector Deal set out the first these new technologies. Advanced phase of implementing the Life therapies are making precision Sciences Industrial Strategy medicines, targeted to the individual patient, a reality here in the UK. through joint commitments between the government This second Life Sciences Sector Rt Hon Greg Clark MP and the sector to invest in the Deal deepens our partnership with industry, universities and charities and United Kingdom’s life sciences Secretary of State for Business, demonstrates how the NHS is pivotal as Energy and Industrial Strategy landscape. a delivery partner. It contains significant The agreements made in the first action to address the Industrial Strategy deal capitalised on the enormous Grand Challenges and our mission to opportunities for growth that the life transform the prevention, diagnosis sciences sector presents for the UK. and treatment of chronic diseases by We are seeing a continual flow of new 2030: it will support the creation of a investments across the health tech cohort of healthy participants that will and pharmaceutical sectors since the enable research into the hidden signs deal was published, with this year’s of disease and ways of diagnosing Rt Hon Matt Hancock MP second deal seeing more life sciences diseases early when interventions Secretary of State for companies investing in the UK and and treatments can be the most Health and Social Care creating high-quality, well-paid jobs. effective. The cohort will involve the public, the research community and Life sciences is a sector that operates industry with the results benefiting at the cutting-edge of technological the whole health service – an example developments. Government of the collective endeavours driving investments in these emerging our modern Industrial Strategy. areas are being matched by greater contributions from the sector, and We are taking action in the work this is building on existing strengths underway from the first Sector Deal, Professor Sir John Bell spanning research and healthcare to and the new commitments set out in GBE, FRS create and grow new industries in the this deal, to achieve the vision of the Regius Professor of Medicine, UK. It is right that NHS patients stand UK as a top-tier hub for life sciences The University of Oxford to benefit from these home-grown globally. The benefits will be felt by innovations. Data-driven technologies UK citizens through economic growth, have the potential to transform the good jobs and a strong and sustainable way the health system works and health service for future generations. support faster and cheaper clinical research. We must ensure the system 2 3 Industrial Strategy Life Sciences Sector Deal 2 Executive summary of NHS data, while maintaining Sector Deal, these programmes are public trust in how data is used building an ecosystem that will help The life sciences industry is one of the most important pillars of and maximising the benefits of life sciences to thrive in the UK: innovation for NHS patients. Our ```A major new commitment, the UK economy, contributing over £70bn a year and 240,000 five new centres of excellence in jobs across the country1. In 2017, a wide coalition of industry and backed by up to £79m of digital pathology and radiology funding, to develop a first-of- charity partners, led by Professor Sir John Bell, published a bold will provide more precise diagnosis, 2 its-kind, world-leading cohort Life Sciences Industrial Strategy that set a clear direction for the applying AI tools to digital images to of healthy participants that will sector’s future growth. detect abnormalities more quickly attract significant global investment and accurately than humans. They The strategy was underpinned by the globally-successful entities; and the need from industry and charities. The will also help to reduce costs. very significant competitive advantages to drive up research and development project will enable research into the UK already possesses – an funding to remain globally competitive. ```We are delivering on our aim to make the hidden signs of disease and the UK a global hub for advanced the development of tools to detect outstanding research base in world- The government’s response to this therapies and building an impressive and diagnose diseases earlier. This class universities; significant capabilities call from industry came with the first end-to-end national infrastructure will lead to a type of ‘predictive in clinical and translational medicine in Life Sciences Sector Deal3, a key part through a £146m commitment prevention’ which is crucial to ensure the NHS; longitudinal datasets within a of the modern Industrial Strategy. to medicines manufacturing. This the NHS has a sustainable future. national healthcare system; the largest The deal included close to £500m includes: doubling capacity at the biotech cluster outside the United of government support for major `` A world-first commitment to Cell and Gene Therapy Catapult States; a highly-productive and skilled new research programmes and over sequence one million whole Manufacturing Centre; three new workforce; and strong capabilities £1bn of new industry investment. genomes in the UK within the advanced therapies treatment centres; in emerging fields, such as digital It brought together partners from next five years including 500,000 and two new innovation centres for health and artificial intelligence (AI). across the pharmaceutical and health through the NHS in addition to the vaccines and medicines manufacturing. Taking these strengths as the basis for tech sectors, charities, government 500,000 in the UK Biobank project. future growth, the strategy set out how agencies and the NHS to deliver its ```The government, industry, the NHS Our broader aspiration is to reach to maintain and build on them under vision at pace. Strong progress is and its partners are delivering on five million genomic analyses in the fierce international competition, and to being made on implementation: their clear commitment to work same timeframe, truly making the UK together to improve the innovation the home of genomic healthcare. capitalise on emerging opportunities. ```An investment of £85m in our and access environment in the It set a roadmap for the UK to create already world-leading genomics `` An additional £50m investment in UK, with strong progress made on whole new industries over the next assets at UK Biobank has attracted our digital pathology programme as implementing the Accelerated two decades in the fields of early significant support for what will be a first step towards making this a truly Access Review4, supported by disease detection and genomics; the largest whole genome sequencing national asset to support early and £86m in government funding. digital technologies and data analytics; project ever undertaken. A £30m improved diagnosis across the UK and and in advanced therapeutics. vanguard study, the first phase of One year on, we are now going deliver more efficient NHS services. further still through this second Life The strategy also set out the areas work, is already underway, sequencing ``` £37.5m funding and a plan for where key developments could fix the first 50,000 participants. Sciences Sector Deal with significant a network of regional Digital additional measures and innovative issues which have slowed down growth; ``` In digital technologies and data Innovation Hubs, providing expert programmes to secure a global lead such as NHS uptake of innovative analytics, we are laying down the clinical research data services, data in the areas of greatest opportunity technologies; the difficulty in scaling building blocks to realise the full analysis and sharing capabilities. for the UK. Together with the first UK biotech companies to create large, potential of the scale and diversity This is part of a wider programme 4 5 Industrial Strategy Life Sciences Sector Deal 2 delivering on the government’s tech ``` Measures to support the supply vision to reform the architecture of capital for innovative firms, of technology in the NHS and helping them to grow, through the make it work better for patients, government’s Patient Capital Review5. Life Sciences clinicians and researchers. Industry partners have responded ``` A wide-ranging new policy package to this significant commitment Sector Deal to support uptake and adoption of with further investment: innovation in the NHS and ensure ```UCB, a global pharmaceutical the UK continues to be a world company, is investing in one Key commitments leader in health tech. Through of their two major global R&D its long-term plan and the recent hubs in the UK. This will involve a branded medicines pricing deal, the purpose-built, state-of-the-art facility NHS will set out how it will be a crucial to enable cutting-edge R&D, early national partner, acting as both a manufacturing and commercial real-world testbed and a beneficiary operations, with planned investment of many of the innovations flowing of £150-200m in the facility and from the life sciences industry. around £1bn total investment Wider policy measures are reinforcing over five years. The transition this approach, including: to the new facility will support ```A suite of measures to make our around 650 high-value jobs across clinical research environment R&D, enabling further collaborations faster, more